R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
7.12.2021 14:28:03 CET | news aktuell GmbH | Press release
RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus.
Only validated products, or products on the temporary protocol, can be sold in the UK after 31 October 2021. Jason Baggaley, Sales Manager of R-Biopharm for Great Britain, commented: “We are proud that our RIDA®GENE Flu & SARS-CoV-2 test was approved and added to the CTDA register and our customers will continue to be able to distinguish between the flu and an infection with the Corona virus.“
Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/news-press
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt, Germany
Tel.: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
Email: s.feiler@r-biopharm.de
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Strong international interest in Security Essen and EUDEX24.9.2026 09:14:52 CEST | Press release
From Albania to Uzbekistan – visitors from almost 90 nations Trade visitors from 89 nations to date, international delegations and companies from more than 40 countries: Security Essen and the new Euro Defence Expo (EUDEX) are bringing guests from numerous parts of the world to Messe Essen this week. Visitors from the Netherlands, Belgium, Switzerland, the UK, Poland, the Czech Republic and France are particularly well represented. But experts are also travelling from more distant countries such as Argentina, Ukraine, Singapore and South Korea to network across borders and find out about the latest security and defence technologies. Security Essen focuses on civil security, whilst the inaugural EUDEX is dedicated to the defence industry.
Major update for Thermomix® and Cookidoo®¬– ecosystem gets smarter, more personalised and more global21.9.2026 13:47:30 CEST | Press release
Thermomix® takes its ecosystem to the next level: With the new Cookidoo® Assistant and Recipe Translation benefits, the largest culinary community gains comprehensive AI features. In addition, Arabic is introduced as a new language option on Thermomix® TM7, following a long-standing community demand.
Grünenthal acquires cancer treatment Stivarga®21.9.2026 12:36:25 CEST | Press release
Latest step in Grünenthal’s strategy to acquire established medicines that serve clear medical needs, leverage its commercial and operational capabilities, and drive growth. Stivarga® (regorafenib) is an established oral treatment for certain advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumours (GIST) and hepatocellular carcinoma (liver cancer). It is approved and available in more than 90 markets worldwide. Grünenthal has invested around €2.6 billion in successful M&A transactions since 2017, significantly strengthening its profitability and further funding its innovative research pipeline.
S&Ds to von der Leyen: Europe must deliver for people and strengthen its sovereignty16.9.2026 09:22:05 CEST | Press release
Strasbourg, 15 september 2026 Ahead of Commission President Ursula von der Leyen’s State of the Union address and debate in Strasbourg on September 16, 2026, the Socialists and Democrats in the European Parliament (S&D) call for a change of direction: away from deregulation and towards better living and working conditions for Europeans, tangible social justice, and a stronger, more sovereign Europe. Iratxe García Pérez, president of the S&D Group in the European Parliament, said: “Europe is facing a choice. Not simply between different policies or political parties, but between two very different visions of our future. One vision is built on fear, power without limits, nationalism and the rule of the strongest. The other vision is the Europe we believe in: a Europe that protects its people, defends democracy and international law, fights climate change, guarantees social rights and has the strength to decide its own future.”* A Europe that delivers for its people The S&D Group has deli
The Iranian People Receive the 2026 Freedom Prize15.9.2026 09:09:43 CEST | Press release
The Friedrich Naumann Foundation for Freedom awards its Freedom Prize 2026 to the courageous people of Iran who are fighting for freedom, civil rights and democracy.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom